Charles Schwab Investment Management Inc Sage Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 462,309 shares of SAGE stock, worth $3.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
462,309
Previous 452,193
2.24%
Holding current value
$3.83 Million
Previous $3.26 Million
23.01%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding SAGE
# of Institutions
195Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$43.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$40.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$38 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$36.9 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$24.9 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $492M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...